Vir Biotechnology (VIR) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$11.70
+5.2% on the day
+93.7% over 12 months
52-week range $5.12 – $11.78
Share price and insider trades
VIR closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$18.0M
Insiders buying0
Insiders selling10
Vir Biotechnology insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 10 sold $18.0M of VIR stock on the open market.
Get emailed when insiders cluster-buy stocks like VIR
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
VIR insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | $1.1M | 5 |
| Q1 2026 | — | 0 | $1.6M | 20 |
| Q4 2025 | — | 0 | $18.3M | 27 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.5×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Vir Biotechnology, Inc. insiders reported open-market purchases totaling $0, while 10 insiders reported sales totaling $18.0M. 52 of 52 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jun 2SEC | Janet NapolitanoDirector | Sell Plan | 3,20021,216 held (−13%) | $9.45 | $30K | +23.8% | — |
| Jun 2SEC | Brent SabatiniSvp, Chief Accounting Officer | Sell Plan | 37961,902 held (−1%) | $9.45 | $4K | +23.8% | — |
| May 4SEC | Vicki L SatoDirector | Sell Plan | 22,0001,078,391 held (−2%) | $10.05 | $221K | +16.4% | — |
| Apr 7SEC | Backer Marianne DeCEO, President | Sell Plan | 72,559948,145 held (−7%) | $9.16 | $665K | +27.7% | — |
| Apr 2SEC | Vicki L SatoDirector | Sell Plan | 22,0001,100,391 held (−2%) | $9.07 | $200K | +29.0% | — |
| Mar 24SEC | Brent SabatiniSvp, Chief Accounting Officer | Sell Plan | 7,71161,902 held (−11%) | $9.12 | $70K | +28.3% | — |
| Mar 3SEC | Vicki L SatoDirector | Sell Plan | 21,8001,122,591 held (−2%) | $9.50 | $207K | +23.2% | — |
| Mar 3SEC | Vicki L SatoDirector | Sell Plan | 2001,122,391 held (−0%) | $9.98 | $2K | +17.2% | — |
| Feb 26SEC | Vicki L SatoDirector | Sell Plan | 42,1771,144,591 held (−4%) | $9.75 | $411K | +20.0% | — |
| Feb 26SEC | Backer Marianne DeCEO | Sell Plan | 14,7621,020,704 held (−1%) | $9.53 | $141K | +22.8% | — |
| Feb 26SEC | Verneuil Vanina DeGeneral Counsel | Sell Plan | 13,700112,982 held (−11%) | $9.82 | $135K | +19.1% | — |
| Feb 26SEC | Verneuil Vanina DeGeneral Counsel | Sell Plan | 3,117126,682 held (−2%) | $9.53 | $30K | +22.8% | — |
| Feb 26SEC | Mark EisnerEvp And Chief Medical Officer | Sell Plan | 1,889154,024 held (−1%) | $9.82 | $19K | +19.1% | — |
| Feb 26SEC | Jason O'byrneCFO | Sell Plan | 1,634162,615 held (−1%) | $9.53 | $16K | +22.8% | — |
| Feb 26SEC | Mark EisnerEvp And Chief Medical Officer | Sell Plan | 1,616155,913 held (−1%) | $9.53 | $15K | +22.8% | — |
| Feb 26SEC | Brent SabatiniSvp, Chief Accounting Officer | Sell Plan | 1,43069,613 held (−2%) | $9.53 | $14K | +22.8% | — |
| Feb 26SEC | Vicki L SatoDirector | Sell Plan | 2001,144,391 held (−0%) | $10.26 | $2K | +14.0% | — |
| Feb 24SEC | Backer Marianne DeCEO | Sell Plan | 19,0391,035,466 held (−2%) | $7.45 | $142K | +57.0% | — |
| Feb 24SEC | Verneuil Vanina DeGeneral Counsel | Sell Plan | 4,445129,799 held (−3%) | $7.45 | $33K | +57.0% | — |
| Feb 24SEC | Jason O'byrneCFO | Sell Plan | 2,089164,249 held (−1%) | $7.45 | $16K | +57.0% | — |
| Feb 24SEC | Mark EisnerEvp And Chief Medical Officer | Sell Plan | 2,089157,529 held (−1%) | $7.45 | $16K | +57.0% | — |
| Feb 24SEC | Brent SabatiniSvp, Chief Accounting Officer | Sell Plan | 1,82971,043 held (−3%) | $7.45 | $14K | +57.0% | — |
| Feb 18SEC | Brent SabatiniSvp, Chief Accounting Officer | Sell Plan | 1,53047,872 held (−3%) | $7.79 | $12K | +50.2% | — |
| Feb 3SEC | Vicki L SatoDirector | Sell Plan | 22,0001,144,391 held (−2%) | $7.71 | $170K | +51.8% | — |
| Jan 5SEC | Vicki L SatoDirector | Sell Plan | 22,0001,166,391 held (−2%) | $5.93 | $130K | +97.3% | — |
| Dec 3SEC | Endurance (cayman) Ltd Svf10% Owner | Sell Plan | 191,85413,728,924 held (−1%) | $5.98 | $1.1M | +95.7% | — |
| Dec 2SEC | Vicki L SatoDirector | Sell Plan | 22,0001,188,391 held (−2%) | $6.00 | $132K | +95.0% | — |
| Dec 1SEC | Softbank Vision Fund (Aiv M1) L.P.10% Owner | Sell Plan | 127,93813,982,271 held (−1%) | $6.39 | $818K | +83.1% | — |
| Dec 1SEC | Softbank Vision Fund (Aiv M1) L.P.10% Owner | Sell Plan | 61,49313,920,778 held (−0%) | $6.44 | $396K | +81.7% | — |
| Nov 26SEC | Endurance (cayman) Ltd Svf10% Owner | Sell Plan | 235,97114,110,209 held (−2%) | $6.38 | $1.5M | +83.4% | — |
| Nov 26SEC | Endurance (cayman) Ltd Svf10% Owner | Sell Plan | 227,80314,346,180 held (−2%) | $6.15 | $1.4M | +90.2% | — |
| Nov 18SEC | Jason O'byrneCFO | Sell Plan | 6,799110,701 held (−6%) | $5.56 | $38K | +110.4% | — |
| Nov 7SEC | Verneuil Vanina DeGeneral Counsel | Sell Plan | 2,38578,210 held (−3%) | $5.16 | $12K | +126.7% | — |
| Nov 4SEC | Vicki L SatoDirector | Sell Plan | 22,0001,210,391 held (−2%) | $5.64 | $124K | +107.4% | — |
| Nov 4SEC | Verneuil Vanina DeGeneral Counsel | Sell Plan | 1,36580,595 held (−2%) | $5.86 | $8K | +99.7% | — |
| Oct 30SEC | Endurance (cayman) Ltd Svf10% Owner | Sell Plan | 24,45314,574,083 held (−0%) | $6.50 | $159K | +80.0% | — |
| Oct 30SEC | Endurance (cayman) Ltd Svf10% Owner | Sell Plan | 10014,573,983 held (−0%) | $6.49 | $649 | +80.3% | — |
| Oct 28SEC | Investment Advisers (uk) Ltd Sb10% Owner | Sell Plan | 66,40314,598,536 held (−0%) | $6.05 | $402K | +93.4% | — |
| Oct 28SEC | Investment Advisers (uk) Ltd Sb10% Owner | Sell Plan | 46,69614,664,939 held (−0%) | $5.96 | $278K | +96.3% | — |
| Oct 24SEC | Investment Advisers (uk) Ltd Sb10% Owner | Sell Plan | 154,38314,711,635 held (−1%) | $5.99 | $925K | +95.3% | — |
| Oct 24SEC | Investment Advisers (uk) Ltd Sb10% Owner | Sell Plan | 144,26614,866,018 held (−1%) | $6.15 | $887K | +90.2% | — |
| Oct 22SEC | Endurance (cayman) Ltd Svf10% Owner | Sell Plan | 220,53515,119,959 held (−1%) | $6.20 | $1.4M | +88.7% | — |
| Oct 22SEC | Endurance (cayman) Ltd Svf10% Owner | Sell Plan | 109,67515,010,284 held (−1%) | $6.30 | $691K | +85.7% | — |
| Oct 17SEC | Endurance (cayman) Ltd Svf10% Owner | Sell Plan | 16,67115,353,338 held (−0%) | $6.07 | $101K | +92.8% | — |
| Oct 17SEC | Endurance (cayman) Ltd Svf10% Owner | Sell Plan | 12,84415,340,494 held (−0%) | $6.10 | $78K | +91.8% | — |
| Oct 14SEC | Softbank Vision Fund (Aiv M1) L.P.10% Owner | Sell Plan | 249,06015,372,309 held (−2%) | $6.14 | $1.5M | +90.6% | — |
| Oct 14SEC | Softbank Vision Fund (Aiv M1) L.P.10% Owner | Sell Plan | 2,30015,370,009 held (−0%) | $6.08 | $14K | +92.4% | — |
| Oct 9SEC | Investment Advisers (uk) Ltd Sb10% Owner | Sell Plan | 466,24215,621,369 held (−3%) | $6.05 | $2.8M | +93.4% | — |
| Oct 9SEC | Investment Advisers (uk) Ltd Sb10% Owner | Sell Plan | 72,13316,087,611 held (−0%) | $5.60 | $404K | +108.9% | — |
| Oct 7SEC | Endurance (cayman) Ltd Svf10% Owner | Sell Plan | 450,34216,233,699 held (−3%) | $5.56 | $2.5M | +110.4% | — |
| Oct 7SEC | Endurance (cayman) Ltd Svf10% Owner | Sell Plan | 73,95516,159,744 held (−0%) | $5.69 | $421K | +105.6% | — |
| Oct 2SEC | Vicki L SatoDirector | Sell Plan | 22,0001,232,391 held (−2%) | $5.84 | $128K | +100.3% | — |
Insiders at Vir Biotechnology, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Endurance (cayman) Ltd Svf10% Owner | — | $9.4M | Dec 3, 2025 | — |
| Investment Advisers (uk) Ltd Sb10% Owner | — | $5.7M | Oct 28, 2025 | — |
| Softbank Vision Fund (Aiv M1) L.P.10% Owner | — | $2.8M | Dec 1, 2025 | — |
| Vicki L SatoDirector | — | $1.7M | May 4, 2026 | — |
| Backer Marianne DeCEO, President | — | $947K | Apr 7, 2026 | — |
| Verneuil Vanina DeGeneral Counsel | — | $218K | Feb 26, 2026 | — |
| Brent SabatiniSvp, Chief Accounting Officer | — | $113K | Jun 2, 2026 | — |
| Jason O'byrneCFO | — | $69K | Feb 26, 2026 | — |
| Mark EisnerEvp And Chief Medical Officer | — | $50K | Feb 26, 2026 | — |
| Janet NapolitanoDirector | — | $30K | Jun 2, 2026 | — |
VIR stock: common questions
Are Vir Biotechnology, Inc. insiders buying VIR stock?
In the past 12 months, 0 insiders reported open-market purchases of VIR worth $0.
Are Vir Biotechnology, Inc. insiders selling VIR stock?
10 insiders reported sales worth $18.0M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is VIR's 52-week range?
Over the past year VIR has traded between $5.12 and $11.78. It last closed at $11.70 on Oct 9, 2026.